24 week approval, page-13

"As i understand it a company with a highly promising drug that has passed phase 2b can file to have approval granted after a 24 week dosing period in the phase III trial rather than the usual 48 weeks. If this approval is obtained then it is estimated that the cost of the trial will be reduced anywhere from 20% to 30%.
That's a saving of $15million to $23 million... this is what i have read but i do not know if AVX management will be pursuing this opportunity"
Can anyone confirm whether this is in-fact possible?
I read this from a newspaper report on Avexa a few months ago.

thanks
orga

seek expert advice